REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.
Articles > Abstract · 2014
Authors: Maurice Perol, Tudor-Eliade Ciuleanu, Oscar Arrieta, Kumar Prabhash, Konstantinos N. Syrigos, Tuncay GÖKSEL, Keunchil Park, Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyzewicz, Sergey Orlov, Conrad R. Lewanski, Ekaterine Alexandris, Annamaria Zimmerman, Nadia Chouaki, William J. John, Sergey Yurasov, Edward B. Garon
JOURNAL OF CLINICAL ONCOLOGY, Journal Indexed in SCI Expanded, International, 2014, vol 32